Table 2 Medical characteristics
From: Masked uncontrolled hypertension in patients with end-stage kidney disease on in-center hemodialysis
Variable | MUCH | Normotension | Total |
|---|---|---|---|
(n = 85) | (n = 19) | (n = 104) | |
Underlying comorbidities, n (%)a | |||
Diabetes (type 1/type 2) | 18 (21.2) | 4 (21.1) | 22 (21.2) |
Heart failure | 26 (30.6) | 1 (5.3) | 27 (26.0) |
Hyperlipidemia | 45 (52.9) | 9 (47.4) | 54 (51.9) |
Anemia | 85 (100.0) | 19 (100.0) | 104 (100.0) |
Primary cause of CKD, n (%)a | |||
Hypertension | 62 (72.9) | 15 (78.9) | 77 (74.0) |
Diabetes and hypertension | 18 (21.2) | 4 (21.1) | 22 (21.2) |
Glomerulonephritis | 3 (3.5) | 0 (0.0) | 3 (2.9) |
Other | 2 (2.4) | 0 (0.0) | 2 (1.9) |
History of myocardial infarction, n (%)b | 17 (20.0) | 1 (5.3) | 18 (17.3) |
History of ischemic/hemorrhagic stroke, n (%) | 5 (5.9) | 1 (5.3) | 6 (5.8) |
Time since hypertension diagnosis (year), median (IQR) | 8 (5–12) | 7 (5–12) | 8 (5–12) |
≤ 8 years, n (%) | 49 (57.6) | 10 (52.6) | 59 (56.7) |
> 8 years, n (%) | 36 (42.4) | 9 (47.4) | 45 (43.3) |
Time since ESKD diagnosis (month), median (IQR) | 74 (25–146) | 27 (25–86) | 68 (25–146) |
Time since dialysis initiation (month), median (IQR) | 72 (24–144) | 24 (24–84) | 48 (24–144) |
≤ 48 months, n (%) | 38 (44.7) | 14 (73.7) | 52 (50.0) |
> 48 months, n (%) | 47 (55.3) | 5 (26.3) | 52 (50.0) |
Pre-dialysis laboratory values, median (IQR) | |||
Hemoglobin (g/L) | 86 (75–91) | 89 (75–93) | 86 (75–91) |
Blood urea nitrogen (mmol/L) | 17.5 (15.2–20.6) | 17.9 (15.4–19.8) | 17.5 (15.2–20.6) |
Serum creatinine (µmol/L) | 858.1 (615.3–984.7) | 821.6 (643.4–908.2) | 858.1 (615.3–984.7) |
Serum corrected total calcium (mmol/L) | 2.31 (2.18–2.55) | 2.34 (2.20–2.59) | 2.31 (2.18–2.55) |
Serum phosphate (mmol/L) | 1.85 (1.59–1.94) | 1.78 (1.57–1.83) | 1.85 (1.58–1.94) |